iBio, Inc. (NYSE:IBIO) CFO Buys $24,999.52 in Stock

iBio, Inc. (NYSE:IBIO) CFO Felipe Duran bought 9,191 shares of the business’s stock in a transaction on Friday, January 10th. The stock was bought at an average cost of $2.72 per share, with a total value of $24,999.52. Following the transaction, the chief financial officer now owns 11,139 shares in the company, valued at $30,298.08. This trade represents a 471.82 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this link.

iBio Trading Down 2.7 %

Shares of IBIO stock traded down $0.07 on Monday, reaching $2.48. The stock had a trading volume of 259,145 shares, compared to its average volume of 162,895. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.37 and a current ratio of 3.37. iBio, Inc. has a 1 year low of $1.02 and a 1 year high of $4.98. The company has a 50 day simple moving average of $2.51 and a 200 day simple moving average of $2.29.

iBio (NYSE:IBIO) last announced its earnings results on Tuesday, November 12th. The company reported ($0.46) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.46). Equities analysts forecast that iBio, Inc. will post -1.74 earnings per share for the current fiscal year.

About iBio

iBio, Inc, a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel.